The bioengineering company Ossium Health has created a new program that offers deep-frozen bone marrow from deceased organ ...

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were ...

“‘Hispanic’ is a very diverse group of people. It’s an ethnicity ... Guzman then referenced a study from 2018 that had major ...

For most people, the word cancer implies that there’s a tumor or mass growing somewhere in the body. However, contrary to ...

Ariane Navarro, a cancer survivor, now works with her doctor to promote umbilical cord blood donation.

accounting for about 80% of acute leukemia in adults. The risk of developing AML increases with age and is more common in middle-aged and elderly people. AML is also not uncommon in individuals ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

Hunter Tate has received news that he is officially in remission, moving from a high-risk to a low-risk protocol and no ...

Precision medicine breakthroughs are expanding treatment options for people with many types of blood cancer, including some that have been hardest to treat, such as acute myeloid leukemia (AML).

Venetoclax is under clinical development by AbbVie and currently in Phase II for Secondary Acute Myeloid Leukemia.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...